Precigen, Inc. Common Stock PGEN

$4.30 -5.29% at last close
Market Cap$1.54 billion
P/E Ratio—
Div Yield—
Volume3.84M
52-Week Range $3.04$8.98

Analyst Ratings

Consensus
Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
Avg. Price Target
$13.67 (+217.8% upside)

Full PGEN forecast & analyst actions →

Key Stats

Today's Range
$4.26 – $4.46
50-Day Range
$3.92 – $8.98
52-Week Range
$3.04 – $8.98
Volume
3.84 million shs
Average Volume
6.55 million shs
Market Cap
$1.54 billion
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
9.30%
Days to Cover
37.16

About Precigen, Inc. Common Stock

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
47
Exchange
XNAS
Listed
2013-08-08

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.